Characteristics of different groups of patients with thrombocytopenia
| Characteristic . | Severe sepsis (n = 17) . | HIT (n = 16) . | OMF (n = 3) . | MDS (n = 4) . | ITP (n = 10) . | AL (n = 6) . | SAA (n = 2) . | Misc (n = 10) . |
|---|---|---|---|---|---|---|---|---|
| Sex: M/F | 14/3 | 10/6 | 3/0 | 3/1 | 4/6 | 5/1 | 2/0 | 6/4 |
| Median age, y | 68 (32-77) | 73 (27-83) | 70 (54-79) | 65 (61-71) | 46 (22-64) | 62 (46-71) | 58 (49-67) | 47 (24-72) |
| Median Hb, g/L | 97 (81-131) | 98 (74-135) | 94 (87-140) | 81 (67-88) | 138 (112-153) | 87 (76-91) | 111 (82-140) | 116 (75-157) |
| Median WBCs, ×109/L | 9.8 (1.5-24.6) | 8.9 (4.8-18.9) | 12.4 (2.5-14) | 3.2 (1.7-37.5) | 10.6 (4.5-25.1) | 3.5 (0.4-19.2) | 4.3 (3.7-4.9) | 3.7 (0.1-127) |
| Median Plts, × 109/L | 69 (7-129) | 69 (19-121) | 25 (7-69) | 31.5 (12-52) | 61 (9-132) | 42.5 (16-83) | 39 (4-74) | 42.5 (7-115) |
| Median ADAMTS13, % | 40 (15-80) | 70 (10-≥100) | 75 (50-≥100) | 87.5 (25-≥100) | ≥100 (≥100-≥100) | ≥100 (40-≥100) | ≥100 (≥100-≥100) | ≥100 (50-≥100) |
| ADAMTS13 30% or lower, no. | 6 | 5 | 0 | 1 | 0 | 0 | 0 | 0 |
| ADAMTS13, %* | 25 (30, 50, 30) | 10 (10, 10, 25) | 25 (25, 30) | |||||
| 20 (30, 25) | 30 (10, 15, 25) | |||||||
| 20 (30, 20, 40) | 30 (50) | |||||||
| 15 (20) | 15 (20) | |||||||
| 30 (25) | 30 (50) | |||||||
| 25 (20) |
| Characteristic . | Severe sepsis (n = 17) . | HIT (n = 16) . | OMF (n = 3) . | MDS (n = 4) . | ITP (n = 10) . | AL (n = 6) . | SAA (n = 2) . | Misc (n = 10) . |
|---|---|---|---|---|---|---|---|---|
| Sex: M/F | 14/3 | 10/6 | 3/0 | 3/1 | 4/6 | 5/1 | 2/0 | 6/4 |
| Median age, y | 68 (32-77) | 73 (27-83) | 70 (54-79) | 65 (61-71) | 46 (22-64) | 62 (46-71) | 58 (49-67) | 47 (24-72) |
| Median Hb, g/L | 97 (81-131) | 98 (74-135) | 94 (87-140) | 81 (67-88) | 138 (112-153) | 87 (76-91) | 111 (82-140) | 116 (75-157) |
| Median WBCs, ×109/L | 9.8 (1.5-24.6) | 8.9 (4.8-18.9) | 12.4 (2.5-14) | 3.2 (1.7-37.5) | 10.6 (4.5-25.1) | 3.5 (0.4-19.2) | 4.3 (3.7-4.9) | 3.7 (0.1-127) |
| Median Plts, × 109/L | 69 (7-129) | 69 (19-121) | 25 (7-69) | 31.5 (12-52) | 61 (9-132) | 42.5 (16-83) | 39 (4-74) | 42.5 (7-115) |
| Median ADAMTS13, % | 40 (15-80) | 70 (10-≥100) | 75 (50-≥100) | 87.5 (25-≥100) | ≥100 (≥100-≥100) | ≥100 (40-≥100) | ≥100 (≥100-≥100) | ≥100 (50-≥100) |
| ADAMTS13 30% or lower, no. | 6 | 5 | 0 | 1 | 0 | 0 | 0 | 0 |
| ADAMTS13, %* | 25 (30, 50, 30) | 10 (10, 10, 25) | 25 (25, 30) | |||||
| 20 (30, 25) | 30 (10, 15, 25) | |||||||
| 20 (30, 20, 40) | 30 (50) | |||||||
| 15 (20) | 15 (20) | |||||||
| 30 (25) | 30 (50) | |||||||
| 25 (20) |
Values in parentheses are ranges unless otherwise indicated.
OMF indicates osteomyelofibrosis; AL, acute leukemia; SAA, severe aplastic anemia; Misc, miscellaneous; Hb, hemoglobin; WBCs, white blood cells; and Plts, platelets.
All plasma samples with ADAMTS13 activity of 30% or less were reanalyzed on different days; individual results (%) of repeated ADAMTS13 assays are in parentheses.